MA43826B1 - Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation - Google Patents

Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation

Info

Publication number
MA43826B1
MA43826B1 MA43826A MA43826A MA43826B1 MA 43826 B1 MA43826 B1 MA 43826B1 MA 43826 A MA43826 A MA 43826A MA 43826 A MA43826 A MA 43826A MA 43826 B1 MA43826 B1 MA 43826B1
Authority
MA
Morocco
Prior art keywords
methods
menin
pyrimidinic
compounds
mll
Prior art date
Application number
MA43826A
Other languages
English (en)
Other versions
MA43826A (fr
Inventor
Yi Wang
Jolanta Grembecka
Dmitry Borkin
Tomasz Cierpicki
Jonathan Pollock
Liansheng Li
Tao Wu
Pingda Ren
Szymon Klossowski
Original Assignee
Kura Oncology Inc
Univ Michigan Regents
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kura Oncology Inc, Univ Michigan Regents filed Critical Kura Oncology Inc
Priority claimed from PCT/US2017/022564 external-priority patent/WO2017161028A1/fr
Publication of MA43826A publication Critical patent/MA43826A/fr
Publication of MA43826B1 publication Critical patent/MA43826B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Abstract

La présente invention concerne des méthodes permettant d' inhiber l'interaction de la ménine avec les oncoprotéines de fusion mll, mll1 et mll2. Les méthodes sont utiles pour le traitement de la leucémie, de cancers solides, du diabète et d'autres maladies dépendant de l'activité des protéines de fusion mll, mlli et mll2 et/ou de la ménine. L'invention concerne également des compositions destinées à être utilisées dans les méthodes de l'invention.
MA43826A 2016-03-16 2017-03-15 Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation MA43826B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662309372P 2016-03-16 2016-03-16
PCT/US2017/022564 WO2017161028A1 (fr) 2016-03-16 2017-03-15 Inhibiteurs substitués de ménine-mll et méthodes d'utilisation

Publications (2)

Publication Number Publication Date
MA43826A MA43826A (fr) 2018-11-28
MA43826B1 true MA43826B1 (fr) 2023-07-31

Family

ID=62683542

Family Applications (1)

Application Number Title Priority Date Filing Date
MA43826A MA43826B1 (fr) 2016-03-16 2017-03-15 Composés thiéno[2,3-d]pyrimidiniques substitués en tant qu'inhibiteurs de ménine-mll et méthodes d'utilisation

Country Status (2)

Country Link
AR (1) AR107891A1 (fr)
MA (1) MA43826B1 (fr)

Also Published As

Publication number Publication date
MA43826A (fr) 2018-11-28
AR107891A1 (es) 2018-06-28

Similar Documents

Publication Publication Date Title
MD3429591T2 (ro) Derivați de tieno[2,3-d]pirimidină substituiți în calitate de inhibitori ai menin-MLL și procedee de utilizare
MA53835A (fr) Lactams bicycliques en tant qu'inhibiteurs de la protéine kinase 1 interagissant avec des récepteurs pour le traitment p.e. de maladies inflammatoires
PH12018501955A1 (en) Bridged bicyclic inhibitors of menin-mll and methods of use
EA201990048A1 (ru) [1,2,4]ТРИАЗОЛО[1,5-a]ПИРИДИНИЛ-ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ СОЕДИНЕНИЯ
MA44322A (fr) Compositions comprenant des souches bactériennes
MA41251B1 (fr) Dérivés de thiéno[2,3-c]pyrrol-4-one comme inhibiteurs erk
MA52856B1 (fr) Composés bicycliques hétéroaryle ou aryle fusionnés et leur utilisation en tant qu'inhibiteurs irak4
MA39034B1 (fr) Composés de quinoline sélectivement substitués
EA201792047A1 (ru) Новые соединения
MA43603A1 (fr) Récepteurs chimériques et leurs procédés d'utilisation
MA38183A1 (fr) Composés pyrrolopyrimidines en tant qu'inhibiteurs de kinase
MX2019003091A (es) Inhibidores de la interaccion de menina-mll.
MX2018015252A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
MA42471B1 (fr) Compositions comprenant des souches bactériennes
MA38347A1 (fr) Dérivés de pyrrolo[2,3-d]pyrimidine en tant qu'inhibiteurs de janus kinases (jak)
EA202091709A1 (ru) Ингибиторы днк-пк
MA39211B1 (fr) Composés tricycliques comme agents anti-cancers
MA40132A1 (fr) Inhibiteurs macrocycliques des interactions protéine/protéine pd-1/pd-l1 et cd80(b7-1)/pd-li
MA39172B1 (fr) Dérivés bicycliques hétérocycliques comme inhibiteurs de bromodomaines
MA40219A (fr) Sels cristallins de (s)-6-((1-acétylpipéridin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA41977B1 (fr) Imidazopyrazinones utilisées comme inhibiteurs de pde1
MA34545B1 (fr) Co-cristaux et sels d'inhibiteurs de ccr3
MA40875A (fr) 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux
EA202091708A1 (ru) Ингибиторы днк-пк